Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).
|06 Dec 2021||$0.02||$0.00||0.00%||11,660,807||$0.02||$0.02||$0.02|
|03 Dec 2021||$0.02||$0.00||0.00%||8,726,096||$0.03||$0.03||$0.02|
|02 Dec 2021||$0.02||$0.00||0.00%||427,684||$0.02||$0.02||$0.02|
|01 Dec 2021||$0.03||$0.00||0.00%||12,764,067||$0.03||$0.03||$0.02|
|30 Nov 2021||$0.03||$0.00||0.00%||1,439,367||$0.03||$0.03||$0.03|
|29 Nov 2021||$0.03||$0.00||0.00%||2,239,983||$0.03||$0.03||$0.03|
|26 Nov 2021||$0.03||$0.00||0.00%||567,684||$0.03||$0.03||$0.03|
|25 Nov 2021||$0.03||$0.00||0.00%||2,795,742||$0.03||$0.03||$0.03|
|24 Nov 2021||$0.03||$0.00||0.00%||1,780,246||$0.03||$0.03||$0.03|
|23 Nov 2021||$0.03||$0.00||0.00%||9,488,992||$0.03||$0.03||$0.03|
|22 Nov 2021||$0.03||$0.00||0.00%||4,275,831||$0.03||$0.03||$0.03|
|19 Nov 2021||$0.03||$0.00||0.00%||21,850,927||$0.03||$0.03||$0.03|
|18 Nov 2021||$0.03||$0.00||0.00%||1,339,823||$0.03||$0.03||$0.03|
|17 Nov 2021||$0.03||$0.00||0.00%||3,575,352||$0.03||$0.03||$0.03|
|16 Nov 2021||$0.03||$0.00||0.00%||1,890,142||$0.03||$0.03||$0.03|
|15 Nov 2021||$0.03||$0.00||0.00%||4,989,566||$0.03||$0.03||$0.03|
|12 Nov 2021||$0.03||$0.00||0.00%||2,629,011||$0.03||$0.03||$0.03|
|11 Nov 2021||$0.03||$0.00||0.00%||2,320,141||$0.03||$0.03||$0.03|
|10 Nov 2021||$0.03||$0.00||0.00%||2,645,363||$0.03||$0.03||$0.03|
|09 Nov 2021||$0.03||$0.00||0.00%||3,998,741||$0.03||$0.03||$0.03|
|08 Nov 2021||$0.03||$0.00||0.00%||9,260,443||$0.03||$0.03||$0.03|
|Mr David Sinclair||Non-Executive Director||Apr 2019||
Dr Sinclair is the co-founder and chairman of Life Biosciences LLC. He is also a tenured professor in the Department of Genetics at Harvard Medical School, a co-director of the Paul F. Glenn Center for the Biology of Aging Research, and serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award. He has co-founded biotechnology and genomics companies which work on aging, neurological, metabolic, infectious and rare diseases.
|Mr Geoffrey Paul Kempler||Non-Executive ChairmanNon-Executive Director||Jun 2005||
Mr Kempler has served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler has experience in investment and business development, has been in charge for the implementation of our strategic plan and the commercialisation of our technology.
|Mr Brian Derek Meltzer||Non-Executive Director||Dec 1999||
Mr Meltzer spent 25 years in investment banking. His breadth of expertise includes property transactions, corporate advisory, corporate finance, management buyouts, venture capital and syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government Innovation Investment Fund. Mr Meltzer is also a Director of the Australia-Israel Chamber of Commerce, Chairman of Independence Australia and Chairman of a privately owned corporate health and wellness business.
|Mr Peter Ashley Marks||Non-Executive Director||Jul 2005||
Mr Marks for over 13 years until the end of August 2014 was a Director of Peregrine Corporate Ltd, an Australian-based investment banking and corporate advisory firm. Mr Marks was until 2016, a Director of Armadale Capital Plc, which has focus on natural resources projects based in Africa with its current investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr Marks is currently a Consultant at Henslow Pty Ltd, a corporate and capital markets advisory firm. Mr. Marks is also a nonexecutive director of Terragenic International Ltd, an unlisted public company and has develop a novel hydrogen fuel system. From September 1998 until March 2001, Mr Marks was working with KPMG Corporate Finance Ltd (Australia), where he rose to Director and was in charge for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these financial institutions, Mr Marks was in charge for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.
|Mr Lawrence Gozlan||Non-Executive Director||Aug 2011||
Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.
|Mr Tristan Edwards||Non-Executive Director||Apr 2019||
Mr Edwards is the co-founder and President of Life Biosciences LLC. He has financial capital markets, regulatory compliance, and fiduciary oversight experience, following a 16 year investment career spanning financial organizations across Australia, London, HK and Singapore. His background has been in senior investment roles at financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career as an analyst with the Australian Commonwealth Department of Finance.
|Mr Phillip Hains||Company Secretary||May 2014||
|Dr David Stamler||Chief Executive Officer||Jan 2021||
|David Stamler||Chief Executive Officer||
|Phillip Hains||Company Secretary||
|HSBC Custody Nominees (Australia) Limited||1,358,556,242||56.44%|
|Life Biosciences Llc||269,905,533||11.21%|
|Jagen Pty Ltd||38,556,497||1.60%|
|1215 Capital Pty Ltd||18,733,028||0.78%|
|Rentuk Shore Pty Ltd||15,641,719||0.65%|
|Capuano Nominees Pty Ltd (The Hartman Investment A/C)||15,000,000||0.62%|
|Andrew Mark Wilmot Seton||14,795,663||0.61%|
|Citicorp Nominees Pty Limited||14,394,030||0.60%|
|Baywick Proprietary Limited (The Retail Discretionary A/C)||14,165,000||0.59%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||12,164,297||0.51%|
|Fagan Harris Pty Ltd (Fagan Harris Super Fund A/C)||9,500,000||0.39%|
|Mr Benjamin Woolvett||7,210,000||0.30%|
|Mr Bill Konstad & Mrs Despina Konstad (The B&D Konstad S F Ac)||6,195,856||0.26%|
|Mr David John Southon (Southon Family A/C)||6,000,000||0.25%|
|Mr Minh Huy Lam||6,000,000||0.25%|
|Mr Huy Nguyen (Huy Nguyen Super Fund A/C)||5,380,195||0.22%|
|Mr Anurag Pandey||5,020,000||0.21%|
|Citos Super Pty Ltd (Citos Pty Ltd Sf A/C)||5,000,000||0.21%|
|Mr Christopher Robert Schroeter||4,778,958||0.20%|